Abstract
This crossover randomized, double-blind, interventional study controlled by standard therapy aims to assess whether the intervention with the SGLT2 inhibitor -dapaglifozin - reduces PA levels, target organ damage, fat profile and change the adipokines levels in patients with resistant hypertension with DM2. We will include 20 patients with resistant hypertension and type 2 diabetes, follo…